"AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints" was originally created and published by Clinical ...

Global Anti Neurofilament L Antibody Industry is to reach a valuation of US$ 145 Billion in 2022, likely to surge at a 11% ...

AstraZeneca said that a new long-acting antibody reduced immunocompromised patients’ risks of contracting symptomatic ...

It says provinces and territories should work toward providing the antibody drug Nirsevimab for all infants before their ...

The Phase Ia trial will evaluate the safety and efficacy of Voyager’s tau-targeting humanised IgG4 monoclonal antibody ...

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly ...

Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.

A trial vaccine has succeeded in generating low levels of antibodies needed to target HIV. It’s a first but much-needed step ...

The H5N1 virus is a long way from becoming adapted to humans, but limited testing and tracking mean we could miss danger ...

Studies in mice and monkeys showed that immune cells could be shepherded to produce antibodies that block a broad swath of ...

In April, the US Food and Drug Administration announced pipeline updates for several drugs intended to treat cancers.

An HIV vaccine candidate triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.